NIBAN1

Across TCGA pan-cancer cohorts, NIBAN1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NIBAN1 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NIBAN1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NIBAN1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and COAD are the cancer types where NIBAN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	29	view →
HNSC	DFS	Median	III,IV	1.000	0.291	.001	26	view →
COAD	DFS	Median	III,IV	0.838	1.000	.037	12	view →
LSCC	DFS	Quartile	All	1.000	0.196	.013	7	view →
LUAD	OS	Quartile	II,III,IV	0.797	0.388	.013	3	view →
GBM	DFS	Median	All	0.300	0.449	.042	2	view →
PDAC	OS	Median	III,IV	0.406	0.788	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

NIBAN1–CCRCC (OS)

Open the CCRCC breakdown →